Company: PACB
Filing Date: 2025-02-07
Form Type: 8-K/A
Source: 0001299130-25-000027
Chunk: 1

Company: PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Filing Date: 2025-02-07
Form: 8-K/A
Chunk 1
---
) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

ITEM 5.02. DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS.

Pacific Biosciences of California, Inc. (the “Company”) is filing this amendment to its Current Report on Form 8-K filed on January 30, 2025, which reported that the Company’s Board of Directors (the “Board”) had appointed Christopher M. Smith as a new director of the Company. At the time of his appointment, Mr. Smith was not appointed to any Board committee. On February 6, 2024, upon the recommendation of the Corporate Governance and Nominating Committee of the Board, the Board appointed Mr. Smith to the Science and Technology Committee of the Board, effective immediately. In connection with his appointment to the Science and Technology Committee, Mr. Smith will receive additional cash compensation as set forth in the Company’s non-employee director compensation policy, as described in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 29, 2024. Concurrent with such appointment, upon the recommendation of the Corporate Governance and Nominating Committee of the Board, the Board appointed Marshall Mohr as chairman of the Audit Committee of the Board in place of Randy Livingston, who will continue to serve as a member of the Audit Committee.

### SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

|                        |     | Pacific Biosciences of California, Inc. |     |                  |
|                        |     | By:                                     |     | /s/ Brett Atkins |
|                        |     |                                         |     | Brett Atkins     |
|                        |     |                                         |     | General Counsel  |
| Date: February 7, 2025 |     |                                         |     |                  |